|
Non-Small Cell Lung Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Three of the strong evidence associations involve RASSF1 methylation on bladder cancer risk (OR = 18.46; 95% CI: 12.69-26.85; I<sup>2</sup> = 0%), MGMT methylation on NSCLC (OR = 4.25; 95% CI: 2.83-6.38; I<sup>2</sup> = 22.4%) and RARB methylation on prostate cancer (OR = 6.87; 95% CI: 4.68-10.08; I<sup>2</sup> = 0%).
|
31202904 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our study provided clear evidence about the association of MGMT hypermethylation with increased risk of NSCLC.
|
29362385 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, the use of the methylation status of P16, RASSF1A, APC, RARβ, DAPK, CDH13, and MGMT could become a promising and powerful biomarker for the detection and screening of NSCLC in blood in clinical settings.
|
28404957 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In NSCLC MGMT promoter methylation is not a prognostic and predictive factor, hence temozolomide has no place.
|
27492578 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The hypermethylation rate of tumor tissue, plasma, BLF, and control tissue of MGMT gene in NSCLC patients were 0.34 ± 0.20, 0.18 ± 0.14, and 0.39 ± 0.23; the statistical heterogeneity across the studies was evaluated by Chi-square and I2-test.
|
28230024 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT methylation was detected in 13% of the NSCLCs.
|
24569633 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The frequencies of MGMT promote methylation ranged from 1.5% to 70.0% (median, 26.1%) in NSCLC tissue and 0.0% to 55.0% (median, 2.4%) in non-cancerous control, respectively.
|
24086261 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aberrant methylation in CDH13 and MGMT was associated with clinicopathologic features of NSCLC.
|
22169480 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Data on the MGMT promoter methylation status in relation to the time to develop intracranial new metastasis or local relapse at the surgical site after brain surgery followed by radiotherapy is limited in non-small-cell lung cancer (NSCLC) patients with a single brain metastasis.
|
22262716 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In conclusion, the present study provides strong evidence for a higher frequency of promoter methylation of the MGMT gene in NSCLC, indicating that it is a common event during the carcinogenesis of NSCLC.
|
21288129 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer.
|
19653236 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
|
18712569 |
2008 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Our results suggest an association between tobacco smoking and an increased incidence of aberrant promoter methylation of the p16 and MGMT genes in non-small cell lung cancer.
|
16533425 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
We tested 61 patients with NSCLC using methylation-specific polymerase chain reaction (MSP) and searched for promoter hypermethylation of the genes p16INK4a, retinoic acid receptor beta-promoter (RARbetaP2), death-associated protein kinase (DAPK), and O6-methylguanine-DNA-methyltransferase (MGMT).
|
15797047 |
2005 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
We examined 514 cases of NSCLC and 84 corresponding nonmalignant lung tissues from 4 countries (USA, Australia, Japan and Taiwan) for the methylation status of 7 genes known to be frequently methylated in lung cancers [p16, RASSF1A (RAS association domain family 1), APC, RARbeta, CDH13, MGMT and GSTP1].
|
12455028 |
2003 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The methylation-specific PCR (MSP) was used to study methylation of the p16, retinoic acid receptor-beta (RARbeta), death-associated protein (DAP) kinase, and O(6)-methylguanine-DNA-methyltransferase (MGMT) genes in 75 NSCLCs [44 adenocarcinomas and 31 squamous cell carcinomas (SCCs)] and 68 BALs from suspected lung cancers.
|
12473584 |
2002 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We determined the frequency of aberrant promoter methylation of the p16, adenomatous polyposis coli (APC), H-cadherin (CDH13), glutathione S-transferase P1 (GSTP1), O6-methylguanine-DNA-methyltransferase (MGMT), retinoic acid receptor beta-2 (RAR beta), E-cadherin (CDH1), and RAS association domain family 1A (RASSF1A) genes in 198 tumors consisting of small cell lung cancers [SCLCs (n = 43)], non-small cell lung cancers [NSCLCs (n = 115)], and bronchial carcinoids (n = 40).
|
12467239 |
2001 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Inactivation of the MGMT gene by promoter hypermethylation alters the pattern of p53 mutation in NSCLC.
|
11719438 |
2001 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The genetic polymorphisms in the coding exons 2, 3 and 4 of MPG and in the enhancer region of MGMT were searched for in DNA samples from a group of 33 non-small-cell lung cancer (NSCLC) patients from Poland.
|
10477488 |
1999 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The O6-MT activity in the U1810 cells showed a dose-dependent decrease after exposure to carmustine.
|
1664221 |
1991 |